Discussing new independent research commissioned by AbbVie and conducted by IQVIA.
The results of a new analysis into current HTA process will be presented and your perspectives on how Scotland is positioned and what policy solutions may be required to ensure continued progress would be valued.
This workshop will be an opportunity to explore the data gap between regulatory initiatives to speed the safe introduction of new medicines, such as conditional marketing authorisation, and the ultimate availability of these medicines to patients in Scotland.
This meeting has been organised and funded by AbbVie and will be chaired by Lewis Macdonald MSP, Chair of the Scottish Parliament Health and Sport Committee and will bring together a group of senior stakeholders including civil servants, MSPs, healthcare policy leaders, clinicians and patient groups.
There will be an opportunity to review the research and to consider recommendations for areas of policy that can be developed to ensure Scotland’s continued reputation at a global level and to maximise opportunities to deliver best access and value for medicines going forward. It is also opportune to discuss such issues in advance of the Health and Sport Committee’s medicines inquiry which is currently calling for views ahead of evidence sessions in early 2020.
Abbvie would welcome your participation and input and hope you are able to join them to discuss the research and share your ideas.
Note: AbbVie is able to reimburse reasonable standard class travel and/or accommodation expenses for those attending on request. Additional logistical details will be circulated before the event.
|Location:||Macdonald Holyrood Hotel|
|Address:||81 Holyrood Road|
For more details contact